We are live on ! Find out more

Onconetix

ONCO

Market cap $2.15M

3.21 USD

+0.18

5.94%

At close Updated Nov 13, 4:00 PM EST

Pre-market

After hours

3.14

-0.07

2.18%

1 day

5.94%

5 days

-54.79%

1 month

-42.16%

3 months

-63.61%

6 months

-91.71%

Year to date

-99.6%

1 year

-99.74%

5 years

-100%

10 years

-100%

About: Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Employees: 2

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Realbotix Provides Update on Nasdaq Listing Timeline

LAS VEGAS--(BUSINESS WIRE)--Realbotix Corp. (TSX-V: XBOT) (Frankfurt: 76M0.F) (OTC: XBOTF) (“Realbotix” or the “Parent Company”), a manufacturer of humanoid robots and AI systems, announces that it has extended the outside date for completion of its all-stock merger transaction between Realbotix LLC (“RealLLC” or the “Subsidiary”), a wholly owned subsidiary of Realbotix, and Onconetix, Inc. (NASDAQ: ONCO) (“ONCO”) to March 31, 2027. “We appreciate shareholder patience as we move closer to compl.

Realbotix Provides Update on Nasdaq Listing Timeline

Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement

Echo Tabletop Priced at $11,950 and Echo Full Body at $59,950; First Production Run of 250 Units Available for 2027 Delivery; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.

Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement

Onconetix Announces Reverse Stock Split

CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company's outstanding common stock. The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 6, 2026. The Company's common stock has been assigned a new CUSIP number, 68237Q500, in connection with the reverse stock split.

Onconetix Announces Reverse Stock Split

Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition

Additional $500,000 Advance to Support Growth Initiatives and Working Capital of Realbotix LLC Total Drawn Under Facility Now $3,000,000; Non-Interest Bearing Facility Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition CINCINNATI, Ohio, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that it has made an additional advance of $500,000 to Realbotix LLC (“Realbotix”), the target of its previously announced pending acquisition, under the strategic bridge financing facility (the “Grid Note”) announced on September 14, 2026. The additional advance brings the total principal outstanding under the facility to $3,000,000.

Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition

CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition

CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition

Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events

Pilot Tests Humanoid Robots as Presenters, Hosts, and Brand Ambassadors Before Live Audiences, Extending Robot Capabilities Beyond One-on-One Interaction into Dynamic, Audience-Facing Environments; Onconetix Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.

Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events

Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series

Entertainment Industry Agreement Reflects Real-World Adoption of Humanoid Robotics Technology Across Education, Healthcare, Hospitality, and Customer Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix's previously announced pending acquisition. Realbotix has entered into an agreement with a recognized streaming platform to feature one of its humanoid robots as a robotic character in an upcoming episode of a popular Emmy-awarded television series.

Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series

Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG

Proteomedix Co-Founder and Proclarix® Co-Developer Returns to Company's Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that its fully-owned Swiss subsidiary, Proteomedix AG (“PMX”), has appointed Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting of Shareholders held on June 22, 2026, at which Thomas Meier, PhD was also re-elected to serve an additional one-year term as Chairman of the Board.

Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG

Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation

Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom's Public Sector Marketplace; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, July 07, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix's previously announced pending acquisition. Realbotix has announced a partnership with Bloom Procurement Services (“Bloom”), a UK public sector procurement specialist, to launch a pilot program deploying socially assistive humanoid robots to combat loneliness and improve wellbeing among elderly residents in Northeast England.

Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation

See News Rankings

Price charts implemented using Lightweight Charts™